Patents by Inventor Anders Hjelholt Pedersen
Anders Hjelholt Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120171765Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: November 18, 2011Publication date: July 5, 2012Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20120107852Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.Type: ApplicationFiled: October 13, 2011Publication date: May 3, 2012Inventors: Torben Halkier, Anders Hjelholt Pedersen, Jens Sigurd Okkels, Kim Vilbour Andersen
-
Patent number: 8084591Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: December 27, 2011Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7754682Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: October 30, 2007Date of Patent: July 13, 2010Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7598056Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: April 18, 2006Date of Patent: October 6, 2009Assignee: Bayer Health Care LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claes Bornaes
-
Patent number: 7517974Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: March 30, 2006Date of Patent: April 14, 2009Assignee: Bayer Healthcare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090088559Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.Type: ApplicationFiled: January 30, 2008Publication date: April 2, 2009Inventors: Torben Halkier, Anders Hjelholt Pedersen, Jens Sigurd Okkels, Kim Vilbour Andersen
-
Patent number: 7511024Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: April 12, 2006Date of Patent: March 31, 2009Assignee: Bayer HealthCare LLCInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090030183Abstract: The invention relates to a conjugate exhibiting interferon ? (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: September 8, 2008Publication date: January 29, 2009Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20090023635Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: ApplicationFiled: October 30, 2007Publication date: January 22, 2009Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7442524Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: October 28, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7427592Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 12, 2006Date of Patent: September 23, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7414022Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: June 26, 2006Date of Patent: August 19, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7371543Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: September 27, 2004Date of Patent: May 13, 2008Assignee: Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 7338788Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: January 24, 2003Date of Patent: March 4, 2008Assignee: Maxygen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Patent number: 7238344Abstract: The present invention provides new interferon ? conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: GrantFiled: December 19, 2002Date of Patent: July 3, 2007Assignee: Maxygen, Inc.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Patent number: 7226999Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and ?1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.Type: GrantFiled: December 3, 2004Date of Patent: June 5, 2007Assignees: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Kim Vilbour Andersen, Anders Hjelholt Pedersen, Per Ola Freskgaard
-
Patent number: 6933367Abstract: The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and ?1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.Type: GrantFiled: November 29, 2001Date of Patent: August 23, 2005Assignees: Maxygen Aps, Maxygen Holdings, Ltd.Inventors: Kim Vilbour Andersen, Anders Hjelholt Pedersen, Per Ola Freskgaard
-
Patent number: 6806063Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: February 12, 2001Date of Patent: October 19, 2004Assignees: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20040013644Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: June 27, 2003Publication date: January 22, 2004Applicants: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes